Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...

Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...

Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

Zydus Lifesciences Ltd enters an agreement with CVS Caremark to add Zituvio, Zituvimet, and Zituvimet XR tablets for diabetes ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to ...

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and Zituvimet XR tablets to its template formulary.

Currently, Nomura is factoring in a 5% decline in US revenues for Zydus Life in financial year 2026, in comparison to financial year 2025.

Housing & Urban Development Corp., Paras Defence and Space Technologies Ltd. and Waaree Energies Ltd. are some stocks that ...

Zydus Wellness Ltd share price was up by 1.60% from the previous closing price of ₹1,976.05. Who are peers of Zydus Wellness Ltd? The peers of Zydus Wellness Ltd are Hindustan Unilever Ltd ...